India's Alembic Pharma quarterly profit rises on strong U.S. generics demand

Alembic Pharmaceuticals

15/05/2026 11:02

May 15 (Reuters) - Indian drugmaker Alembic Pharmaceuticals ALEM.NS posted a 29.2% rise in fourth-quarter profit on Friday, aided by strong demand for its generic drugs and new launches in its key United States market.

The drugmaker's consolidated profit rose to 2.03 billion rupees ($21.12 million) in the quarter ended March 31, from 1.57 billion rupees a year ago.

Revenue from its U.S. generics business jumped 11% to 5.64 billion rupees, driven by key product launches such as UTI treatment drug Pivya and gains in market share across select therapies.

Overall revenue rose 4.4% to 18.48 billion rupees during the quarter.

The company and several of its Indian peers that make generic drugs derive a significant share of revenue from the U.S.

Larger rivals Cipla CIPL.NS and Dr Reddy's Laboratories REDY.NS both reported weaker-than-expected fourth-quarter profits.

($1 = 96.1025 Indian rupees)

 (Reporting by Devika Nair and Mridula Kumar in Bengaluru; Editing by Nivedita Bhattacharjee)

 ((Devika.MadhusudhananNair@thomsonreuters.com;))